Is it safe to use Otrivin (xylometazoline) during pregnancy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 11, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Otrivin (Xylometazoline) Use During Pregnancy

Otrivin (xylometazoline) should be avoided during pregnancy due to insufficient safety data, though short-term use for severe nasal congestion may be considered when benefits clearly outweigh risks, particularly after the first trimester.

Safety Profile and Evidence

The available evidence for xylometazoline use in pregnancy is extremely limited:

  • No formal pregnancy safety classification exists for xylometazoline in major obstetric or rheumatology guidelines 1
  • Animal studies show potential risks, placing it in the former FDA Category C classification (similar to hydroxyzine, which is recommended to be avoided in pregnancy) 2
  • Lack of controlled human studies means the teratogenic potential and fetal effects remain unknown 3, 4

Clinical Considerations

Why Caution is Warranted

  • Systemic absorption occurs with nasal decongestants, potentially affecting uterine blood flow through vasoconstriction 3
  • First trimester exposure carries highest risk for any medication, as this is the period of organogenesis when congenital malformations are most likely to occur 1
  • Most pregnant women overestimate medication risks, but in this case, the lack of safety data justifies caution 5

When Use Might Be Considered

If nasal congestion is severe enough to impact maternal health (inability to sleep, eat, or breathe adequately):

  • Limit to second and third trimesters when organogenesis is complete 1
  • Use the lowest effective dose for the shortest duration possible 3, 4
  • Maximum 3 times daily at 0.025% concentration based on pediatric safety data 6
  • Duration should not exceed 3-5 days to prevent rebound congestion and minimize fetal exposure 3

Safer Alternatives

Saline nasal spray (0.9%) is the preferred first-line treatment for nasal congestion in pregnancy:

  • No systemic absorption or fetal risk 6, 3
  • Can be used unlimited times daily throughout all trimesters 6
  • Effective for symptom relief when used frequently 3, 4

Other Options

  • Chlorpheniramine has the longest safety record among antihistamines if allergic rhinitis is the cause 2
  • Loratadine and cetirizine are former FDA Category B drugs with more favorable safety profiles than xylometazoline 2
  • Non-pharmacological measures including humidifiers, nasal strips, and elevation of the head during sleep 3, 4

Common Pitfalls to Avoid

  • Do not assume OTC medications are automatically safe - approximately 10% of birth defects are linked to medication exposure during pregnancy 4
  • Avoid combination cold medications that may contain multiple active ingredients, increasing exposure risks 3
  • Do not use beyond 3-5 days even if symptoms persist, as this increases systemic exposure without additional benefit 3
  • Discuss all OTC medication use with your healthcare provider before starting, as individual risk-benefit assessment is essential 3, 4, 7

Bottom Line

Start with saline nasal spray as the safest option 6, 3. If xylometazoline is absolutely necessary due to severe symptoms affecting maternal well-being, use only after the first trimester, at the lowest dose, for the shortest duration (maximum 3-5 days), and only after discussing with your obstetrician 1, 3.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Hydroxyzine Use in Pregnancy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Over-the-Counter Medications in Pregnancy.

American family physician, 2014

Research

Safety of Over-the-Counter Medications in Pregnancy.

MCN. The American journal of maternal child nursing, 2019

Research

Perceptions of medicine use among pregnant women: an interview-based study.

International journal of clinical pharmacy, 2019

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.